Almirall, S.A. Share Price

Equities

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME 16:35:30 17/05/2024 BST 5-day change 1st Jan Change
9.27 EUR -0.97% Intraday chart for Almirall, S.A. +1.20% +10.03%

Financials

Sales 2024 * 980M 1.07B 83.92B Sales 2025 * 1.08B 1.17B 92.48B Capitalization 1.94B 2.11B 166B
Net income 2024 * 24M 26.08M 2.06B Net income 2025 * 63M 68.46M 5.39B EV / Sales 2024 * 1.98 x
Net cash position 2024 * 2.34M 2.55M 201M Net cash position 2025 * 77.1M 83.79M 6.6B EV / Sales 2025 * 1.73 x
P/E ratio 2024 *
77.2 x
P/E ratio 2025 *
29.8 x
Employees 1,904
Yield 2024 *
2.02%
Yield 2025 *
2%
Free-Float 34.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.97%
1 week+1.20%
Current month+8.17%
1 month+13.39%
3 months+7.67%
6 months+7.73%
Current year+10.03%
More quotes
1 week
9.12
Extreme 9.115
9.96
1 month
8.23
Extreme 8.23
9.96
Current year
7.85
Extreme 7.85
9.96
1 year
7.16
Extreme 7.16
10.08
3 years
7.16
Extreme 7.16
15.35
5 years
7.16
Extreme 7.16
18.50
10 years
7.16
Extreme 7.16
19.36
More quotes
Managers TitleAgeSince
Chief Executive Officer - 24/07/14
Director of Finance/CFO 54 10/11/19
Chief Tech/Sci/R&D Officer - 06/07/21
Members of the board TitleAgeSince
Director/Board Member - 31/12/15
Director/Board Member 65 30/06/20
Director/Board Member 65 31/12/18
More insiders
Date Price Change Volume
17/05/24 9.27 -2.52% 166,941
16/05/24 9.51 +1.39% 290,154
15/05/24 9.38 +1.96% 338,265
14/05/24 9.2 -0.92% 708,051
13/05/24 9.285 +1.36% 814,503

Delayed Quote BME, May 17, 2024 at 04:35 pm

More quotes
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
9.27 EUR
Average target price
11.28 EUR
Spread / Average Target
+21.65%
Consensus